Shay Capital’s PharmaCyte Biotech PMCB Stock Holding History

Shay Capital’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,015,666	Closed	-$2.44M	–	383
2022 Q3	$2.44M	Buy	1,015,666 +32,968	+3%	+$83.4K	0.53%	30
2022 Q2	$2.2M	Buy	982,698 +38,032	+4%	+$83.1K	0.44%	45
2022 Q1	$2.17M	Buy	944,666 +282,329	+43%	+$627K	0.28%	54
2021 Q4	$1.66M	Buy	662,337 +647,731	+4,435%	+$1.78M	0.27%	62
2021 Q3	$46K	Buy	+14,606	New	+$51.3K	0.01%	494

Other funds holding PMCB

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Shay Capital's PMCB Position: Q4 2022 in Review

Shay Capital sold out of PharmaCyte Biotech (PMCB) in Q4 2022, closing a stake of 1,015,666 shares — an estimated $2.44M sold.

Shay Capital first reported a position in PMCB in Q3 2021 and held it in 5 quarters. The position peaked at $2.44M in Q3 2022. 30 funds tracked by Wall St. Rank hold PMCB as of Q4 2022.

Shay Capital reported no remaining PharmaCyte Biotech position as of Q4 2022 after selling out during the quarter.
Shay Capital sold 1,015,666 PharmaCyte Biotech shares in Q4 2022, an estimated $2.44M.
Shay Capital first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 5 quarters.
Shay Capital's PharmaCyte Biotech position peaked at $2.44M in Q3 2022.
30 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2022.

Based on Shay Capital's 13F filing for Q4 2022, filed 14 Feb 2023.